Vangacin 500/Vangacin 1 g

Vangacin 500/Vangacin 1 g



Able Medical


Universal Medical Industry


Able Medical
Concise Prescribing Info
Vancomycin HCl
Diphtheroid endocarditis; in combination w/ either rifampin, aminoglycoside or both in early-onset prosthetic valve endocarditis caused by Staph epidermidis or diphtheroids; endocarditis caused by enterococci (eg, Enterococcus faecalis) in combination w/ aminoglycoside; staphylococcal endocarditis; monotherapy or in combination w/ aminoglycoside for endocarditis caused by Strep viridans or Strep bovis. Clostridium difficile-associated diarrhea/staphylococcal enterocolitis. Serious or severe infection caused by susceptible strains of MRSA; initial therapy when MRSA is suspected; infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobials. For patients who are allergic to penicillin; cannot receive or failed to respond to other drugs, including penicillins or cephalosporins. Infections due to Staph (eg, septicemia, bone, lower resp tract, skin & skin structure infections); as adjunct to appropriate surgical measures when Staph infections are localized & purulent. Mild, moderate, & severe C. difficile infections in pregnant women. Alternative agent for prevention of transmission of group B strep disease from mothers to newborns. Prevention of bacterial endocarditis. Alternative prophylactic agent for prevention of enterococcal endocarditis in penicillin-allergic adults & childn w/ congenital heart disease, rheumatic or other acquired valvular heart dysfunction, prosthetic heart valves, who undergo certain GI, biliary tract, or genitourinary surgery of instrumentation likely to cause transient bacteremia & increase the risk of endocarditis. Prophylaxis against infective endocarditis undergoing dental, oral, or upper resp tract surgery & w/ underlying cardiac conditions.
Dosage/Direction for Use
Intermittent or continuous IV infusion Administer at rate not >10 mg/min or over a period of at least 60 min, whichever is longer. Intermittent IV infusion is given over a period of at least 1 hr. Adult Endocarditis, staphylococcal infections 500 mg IV every 6 hr or 1 g IV every 12 hr. C. difficile-associated diarrhea/staphylococcal enterocolitis 500 mg to 2 g in 4 divided doses for 7-14 days. Patient w/ mild to moderate renal insufficiency Initially not <15 mg/kg; CrCl 100 mL/min 1,545 mg/24 hr; 90 mL/min 1,390 mg/24 hr; 80 mL/min 1,235 mg/24 hr; 70 mL/min 1,080 mg/24 hr; 60 mL/min 952 mg/24 hr; 50 mL/min 770 mg/24 hr; 40 mL/min 620 mg/24 hr; 30 mL/min 465 mg/24 hr; 20 mL/min 310 mg/24 hr; 10 mL/min 155 mg/24 hr. Maintenance dose: 250-1,000 mg once every several days. Adult, geriatric Community-acquired pneumonia 15-20 mg/kg/dose every 8-12 hr for 7-21 days. Hospital-acquired or ventilation-associated pneumonia 15 mg/kg/dose every 8-12 hr for 7 days; seriously ill patient Loading dose of 25-30 mg/kg/dose. Sepsis/septic shock (empiric treatment or treatment for specific sensitive organism) 15-20 mg/kg/dose every 8-12 hr; seriously ill patient Loading dose of 25-30 mg/kg. Ped Endocarditis, Staph infections ≥1 mth 10 mg/kg/dose IV given every 6 hr; up to 1 mth Total daily IV dose may be lower. Neonates Initially 15 mg/kg followed by 10 mg/kg every 12 hr in the 1st wk of life & every 8 hr thereafter up to 1 mth. Pseudomembranous colitis/Staph enterocolitis 40 mg/kg/day given in 3 or 4 divided doses for 7-10 days. Max: 2 g/day. Prophylaxis against infective endocarditis Childn & adolescent Dental, oral or upper resp tract surgery 20 mg/kg/dose administered 1 hr prior to procedure. Meningitis Infants >1 mth, childn & adolescent 15 mg/kg/dose every 6 hr (for empiric therapy, use in combination w/ 3rd-generation cephalosporin); for MRSA, treat for 2 wk (w/ or w/o rifampin). Pneumonia (group A Strep: alternative to ampicillin or penicillin in β-lactam allergic patients), presumed bacterial (in addition to recommended antibiotic therapy), S. pneumoniae, moderate to severe infection (MICs to penicillin 2 mcg/mL) (alternative to ampicillin or penicillin), S. aureus (methicillin susceptible) (alternative to cefazolin/oxacillin); S. pneumoniae, moderate to severe infection (MICs to penicillin 4 mcg/mL) (alternative to ceftriaxone in β-lactam allergic patients) 40-60 mg/kg/day divided every 6-8 hr. S. aureus, moderate to severe infection (methicillin resistant +/ clindamycin susceptible) (preferred) 40-60 mg/kg/day divided every 6 to 8 hr or dosing to achieve AUC/MIC > 400. Alternative regimen: 60 mg/kg/day divided every 6 hr for 7-21 days, depending on severity. Healthcare-associated pneumonia, S. aureus (methicillin-resistant) Infant, childn, adolescent 60 mg/kg/day divided every 6 hr for 7-21 days depending on severity. Prophylaxis against infective endocarditis Childn & adolescent Dental, oral or upper resp tract surgery 20 mg/kg dose administered 1 hr prior to procedure; GI/GU procedure 20 mg/kg (+ gentamycin 1.5 mg/kg) administered 1 hr prior to surgery.
Special Precautions
Do not use in hypersensitive patients. May develop anaphylactoid reactions during or soon after the rapid infusion. Transient or permanent ototoxicity in patients who have excessive dose, underlying hearing loss, or receiving concomitant therapy w/ another ototoxic agent (eg, aminoglycoside). C. difficile-associated diarrhea. Reversible neutropenia. Thrombophlebitis may occur. Prolonged use may result in overgrowth of non-susceptible organisms. Renal impairment. May cause ear nerve damage in fetus. Pregnancy & lactation.
Adverse Reactions
Onset of pseudomembranous colitis symptoms; reversible neutropenia; anaphylactoid reactions (eg, dyspnea, hypotension, pruritus, urticaria, or wheezing), upper body flushing or pain, chest & back muscle spasm; inj site inflammation; hearing loss; drug rash w/ eosinophilia & systemic symptoms. Anaphylaxis, chills, drug fever, eosinophilia, nausea, rashes, (including exfoliative dermatitis). Stevens-Johnson syndrome, toxic epidermal necrolysis.
Drug Interactions
May enhance nephrotoxic effect of aminoglycoside, colistimethate. May diminish therapeutic effect of BCG, Na picosulfate, typhoid vaccine. Diminished therapeutic effect w/ bile acid sequestrants. May enhance neuromuscular-blocking effect of neuromuscular-blockers. May increase serum conc w/ NSAIDs. Enhanced nephrotoxic effect w/ piperacillin.
MIMS Class
Other Antibiotics
ATC Classification
J01XA01 - vancomycin ; Belongs to the class of glycopeptide antibacterials. Used in the systemic treatment of infections.
Vangacin 1 g powd for inj 1 g
Vangacin 500 powd for inj 500 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in